Navigating Multiple Sclerosis: Q&A with Dr. Ben Thrower

🎯There is a risk of liver function issues with certain disease-modifying therapies for multiple sclerosis.

👩‍⚕️B-cell therapies like cmta okus and okus brium can lead to loss of neural reserve and progression independent of relapse activity.

📊Studies suggest that relapsing multiple sclerosis may progress to secondary progressive MS without treatment.

🔬Neuroimaging, EMG, and nerve conduction studies can help determine the cause of weakness in multiple sclerosis.

😷B-cell therapies carry a low risk of developing PML, especially in cases where there is no prior exposure to natalism AB.

Are there any disease-modifying therapies for multiple sclerosis that can affect liver function?

—Yes, certain disease-modifying therapies, such as interferon drugs, carry a risk of liver function issues.

Can B-cell therapies like cmta okus and okus brium cause progression independent of relapse activity?

—Yes, loss of neural reserve and smoldering inflammation can contribute to progression even without new MRI activity.

Is it common for relapsing multiple sclerosis to progress to secondary progressive MS?

—Without treatment, the natural history of multiple sclerosis shows that most people with relapsing MS eventually transition to secondary progressive MS.

How can the cause of weakness in multiple sclerosis be determined?

—Tests such as neuroimaging, EMG, and nerve conduction studies can help identify whether weakness is due to MS progression or other factors like pinched nerves.

What is the risk of developing PML while taking B-cell therapies?

—B-cell therapies like cmta okus and okus brium carry a low risk of developing PML, especially when there is no prior exposure to natalism AB.

00:05Dr. Ben Thrower introduces and discusses various topics related to multiple sclerosis.

01:27He explains the risk of liver function issues with certain disease-modifying therapies.

03:36Dr. Thrower highlights the potential impact of B-cell therapies on neural reserve and progression independent of relapse activity.

06:41He discusses the natural history of multiple sclerosis and the likelihood of progression from relapsing MS to secondary progressive MS.

09:20Dr. Thrower explains how to determine the cause of weakness in multiple sclerosis using various diagnostic tests.

12:55He addresses the risk of developing PML while taking B-cell therapies and clarifies the low risk associated with those therapies.